Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery

British Journal of Haematology

Volumn 104, Issue 2, 1999, Pages 230-240

  Bara, Lucienne ^a,c   Planes, André ^b   Samama, Meyer Michel ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b Clinique du Mail   (France)

^c Lab de Thrombose Exp   (France)

Author keywords

Anti IIa; Anti Xa; D dimers; Hip surgery; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; D DIMER; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN A; TINZAPARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HIP SURGERY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; DOUBLE-BLIND METHOD; ENOXAPARIN; FACTOR XA; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POSTOPERATIVE HEMORRHAGE; PROTHROMBIN; THROMBOSIS; VENOUS THROMBOSIS;

EID: 0032957278     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01153.x     Document Type: Article

References (45)

1. Abildgaard, U. (1993) Heparin/low molecular weight heparin and tissue pathway inhibitor. Haemostasis, 23, (Suppl. 1), 103-106.
2. Bara, L., Bloch, M.F., Zitoun, D., Samama, M., Collignon, E. Frydmann, A., Uzan, A. & Bouthier, J. (1993) Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation and release of tissue factor pathway inhibitor. Thrombosis Research, 69, 443-452.
3. Bara, L., Combe-Tamzali, S., Conard, J., Horellou, M.H. & Samama, M. (1987) Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (heptest). Haemostasis, 17, 127-133.
4. Bara, L., Leizorovicz, A., Picolet, H. & Samama, M.M. (1992) Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with logiparin (LMWH) or unfractionated heparin. Thrombosis Research, 65, 641-650.
5. Bara, L., Mardiguian, J. & Samama, M. (1990) In vitro effect on heptest of low molecular weight heparin fraction and preparations with various anti-IIn and anti-Xa activities. Thrombosis Research, 57, 585-592.
6. Bara, L. & Samama, M.M. (1989) Antithrombotic activity of various heparin oligosaccharides in relation with their in vitro and ex vivo anti-Xa activity in the rabbit. (Abstract). Thrombosis and Haemostasis, 62, 422.
7. Bergqvist, D., Burmark, U.S., Frisell, J., Hallböök, T., Lindblad, B., Risberg, B., Torngren, S. & Wallin, C. (1986) Low molecular weight heparin once daily compared with conventional low dose heparin twice daily: a prospective double-blind multicentre trial on prevention of postoperative thrombosis. British Journal of Surgery, 73, 204-208.
8. Bounameaux, H., de Moerloose, P., Perrier, A. & Reber, C. (1994) Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: an overview. Thrombosis and Haemostasis, 71, 1-6.
9. Buchanan, M.R., Boneu, B., Ofosu, F. & Hirsh, J. (1985) The relative importance of thrombin inhibition, of factor-Xa inhibition to the antithrombotic effect of heparin. Blood, 65, 198-201.
10. Caen, J.P. (1988) A randomized double-blind study between a low molecular weight heparin Kabi-2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. Thrombosis and Haemostasis, 59, 216-220.
11. Carter, C.J., Kelton, J.G., Hirsh, J., Cerskus, A., Santos, A.V. & Gent, M. (1982) The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood, 59, 1239-1245.
12. Clagett, G.P., Anderson, F.A., Heit, J., Levine, M.N. & Brownell Wheeler, H. (1995) Prevention of venous thromboembolism. Proceedings, Consensus Conference on Antithrombotic Therapy (4th American College of Chest Physicians), Tucson, Arizona, April 1995. Chest, 108, 312S-334S.
13. Collins, R., Scrimgeour, A., Yusuf, S. & Peto, R. (1988) Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. New England Journal of Medicine, 318, 1162-1173.
14. Dahl, O.E., Andreaseen, G., Muller, C., Mathiosen, P., Nyhus, S. & Aspelin, T. (1995) The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis and pulmonary embolism 35 days after hip replacement surgery. (Abstract). Thrombosis and Haemostasis, 73, 1094.
15. Fernandez, F.A., N'Guyen, P., Van Ryn, J., Ofosu, F.A., Hirsh, J. & Buchanan, M.R. (1986) Hemorrhagic doses of heparin and other glycosominoglycans induce a platelet effect. Thrombosis Research, 43, 491-495.
16. Francis, C.W., Pellegrini, V.D., Marder, V.J., Totterman, S., Harris, C.M., Rubengabriel, K., Azodo, M.V. & Leibert, K.H. (1992) Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. Journal of the American Medical Association, 267, 2911-2915.
17. Frydman, A.M., Bara, L., Roux, Y., Woler, M., Chauliac, F. & Samama, M.M. (1988) The antithrombotic activity of enoxaparin, a low molecular weight heparin, in humans given subcutaneous doses of 20 to 80 mg. Journal of Clinical Pharmacology, 26, 609-618.
18. Haether, A., Balfour, F. & Balfour, J.A. (1994) Tinzaparin: a review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs, 48, 638-660.
19. Hirsh, J., Ofosu, F.A., Levine, M., Verstracte, M., Vermylen, J., Lijnen, H.R. & Arnout, J. (1987) The development of low molecular weight heparins for clinical use. Thrombosis and Haemostasis (ed. by M. Verstraete, J. Vermylen, R. Lijnen and J. Amout), pp. 328-348. Leuven University Press.
20. Holmer, E., Mattson, C. & Nilsson, S. (1982) Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin in rabbits. Thrombosis Research, 25, 475-485.
21. Hull, R.D., Raskob, G., Pineo, G., Rosenbloom, D., Evans, W., Mallory, T., Anquist, K., Smith, F., Hughes, G., Green, D., Elliot, G., Panju, A. & Brant, R. (1993) A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. New England Journal of Medicine, 329, 1370-1376.
22. Hull, R.D., Raskob, G.E., Pineo, G.F., Green, D., Trowbridge, A.A., Elliott, G., Lerner, R.G., Hall, J., Sparling, T., Brettell, H.R., Norton, J., Carter, C.J., George, R., Merli, G., Ward, J., Mayo, W., Rosenbloom, D. & Brant, R. (1992) Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. New England Journal of Medicine, 326, 975-982.
23. Kakkar, V.V. (1995) Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE). Thrombosis and Haemostasis, 74, 364-368.
24. Koller, M., Schock, U., Buchmann, P., Largiader, F., Von Felten, A. & Frick, P.G. (1986) Low molecular weight heparin (Kabi-2165) as thromboprophylaxis in elective visceral surgery: a randomized double-blind study versus unfractionated heparin. Thrombosis and Haemostasis, 56, 243-246.
25. Lassen, M.R., Borris, L.C., on behalf the Danish Prolonged Prophylaxis Study Group (1996) Prolonged prophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty, a placebo controlled study. (Abstract). Drugs, 52, (Suppl.), 47-54.
26. Leizorovicz, A., Bara, L., Samama, M.M. & Haugh, M.C. (1992) Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis, 23, (Suppl. 1), 89-98.
27. Leizorovicz, A., Haugh, M.C., Chapuis, F.R., Samama, M.M. & Boissel, J.P. (1992) Low molecular weight heparin in prevention of perioperative thrombosis. British Medical Journal, 305, 913-920.
28. Leizorovicz, A., Picolet, H., Peyrieux, J.C., Boissel, J.P. and the HBPM research group (1991) Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of logiparin and standard heparin. British Journal of Surgery, 78, 412-416.
29. Levine, M.N., Planes, A., Hirsh, J., Goodyear, M., Vochelle, N. & Gent, M. (1989) The relationship between antifactor-Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thrombosis und Haemostasis, 62, 940-944.
30. Leyvraz, P., Bachmann, F., Hoek, J., Buller, H.R., Postel, M., Samama, M.M. & Vandenbrock, M.D. (1991) Prevention of deep vein thrombosis after hip replacement: randomized comparison between unfractionated heparin and low molecular weight heparin. British Medical Journal, 303, 543-548.
31. Leyvraz, P.F., Richard, J., Bachmann, F., Van Melle, G., Treyvaud, J.M., Livio, J.J. & Candardjis, G. (1983) Adjusted versus fixed dose subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. New England Journal of Medicine, 309, 954-958.
32. Matthiasson, S.E., Lindblad, B., Stjernquist, U. & Bergqvist, D. (1993) The haemorrhagic effect of low molecular weight heparins, dermatan sulfate and hirudin. Haemostasis, 25, 203-211.
33. Nurmohamed, M.T., Rosendaal, F.R., Buller, H.R., Dekker, E., Hommes, D.W., Vandenbroucka, J.P. & Berret, E. (1992) Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet, 340, 152-156.
34. Ockelford, P.A., Carter, C.J., Cerskus, A., Smith, C.A. & Hirsh, J. (1982a) Comparison of the ex vivo hemorrhagic and antithrombotic effects of low antithrombin III affinity heparin fraction. Thrombosis Research, 27, 679-690.
35. Ockelford, P.A., Carter, C.J., Mitchell, L. & Hirsh, J. (1982b) Discordance between the anti-Xa activity and the antithrombotic activity of the ultra-low molecular weight heparin fraction. Thrombosis Research, 27, 401-409.
36. Petersen, L.C., Valentin, S. & Hedner, U. (1995) Regulation of the extrinsic pathway system in health and disease: the role factor VIIa and tissue factor pathway inhibitor. Thrombosis Research, 79, 41-47.
37. Planes, A., Samama, M.M., Lensing, A.W.A., Buller, H.R., Barre, J., Vochelle, N. & Beau, B. (1999) Prevention of deep vein thrombosis after hip replacement: comparison between two low molecular weight heparins, tinzaparin and enoxaparin. Thrombosis and Haemostasis, in press.
38. Planes, A., Vochelle, N., Darmon, Y., Fagola, M., Bellaud, M. & Huet, Y. (1996) Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet, 348, 224-228.
39. Rochemaure, J., Laaban, J.P., Achkar, A., Fretault, J. & Samama, M. (1995) Intérêt du dosage des D-Dimères dans l'approche diagnostique des accidents thromboemboliques veineux. Bulletin de l'Académie Nationale de Médecine, 179, 299-316.
40. Rothermel, J.E., Weissinger, J.B. & Stinchfiels, F.E. (1973) Dextran 40 and thromboembolism in total hip replacement surgery. Archives of Surgery, 106, 135-137.
41. Rowbothman, B.J., Whitaker, A.N., Harrison, J., Murtaugh, P., Reasbeck, P. & Bowie, F.J.W (1992) Measurement of crosslinked fibrin derivatives in patients undergoing abdominal surgery: use in the diagnosis of post operative venous thrombosis. Blood Coagulation and Fibrinolysis, 3, 25-31.
42. Samama, M., Bernard, P., Bonnardot, V.P., Tissot, E., Lanson, Y. & Combe-Tamzali, S. (1988) Low molecular weight heparin (enoxaparin) compared with unfractionated heparin thrice in day in prevention of post-operative thrombosis. British Journal of Surgery, 75, 128-131.
43. The Danish enoxaparin Study Croup (1991) Low molecular weight heparin (enoxaparin) vs dextran 70. Archives of Internal Medicine, 151, 1612-1624.
44. The DVTENOX Study Group (1993) Markers of hemostatic system activation in acute deep vein thrombosis: evolution during the first days of heparin treatment. Thrombosis and Haemostasis, 70, 909-914.
45. Turpie, A.G.G., Levine, M.N., Hirsh, J., Carter, C.J., Jay, R.M., Powers, P.J., Andrew, M. Hull, R.D. & Gent, M. (1987) A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing hip surgery. New England Journal of Medicine, 315, 925-929.